Ftse Mib
35.390,52
-0,06%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.676,92
-0,13%
Bitcoin
66.923,14
2,58%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Syros Pharmaceuticals Inc (SYRS) Syros Pharmaceuticals Inc (SYRS) Notizie

SYRS

Syros Pharmaceuticals (SYRS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SYRS
DataOraFonteTitoloSimboloCompagnia
14/05/202413:30Business WireSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
14/05/202412:42Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRSSyros Pharmaceuticals Inc
07/05/202415:00Business WireSyros to Participate in Upcoming Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
07/05/202413:00Business WireSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
09/04/202413:00Business WireSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
02/04/202422:30Business WireSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202412:30Business WireSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202411:57IH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:SYRSSyros Pharmaceuticals Inc
25/03/202412:00Business WireSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialNASDAQ:SYRSSyros Pharmaceuticals Inc
20/03/202412:00Business WireSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
27/02/202413:00Business WireSyros to Participate in TD Cowen 44th Annual Health Care ConferenceNASDAQ:SYRSSyros Pharmaceuticals Inc
15/02/202402:56Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRSSyros Pharmaceuticals Inc
14/02/202402:22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
08/01/202413:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
08/01/202413:00Business WireSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of TamibaroteneNASDAQ:SYRSSyros Pharmaceuticals Inc
26/12/202323:19Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
19/12/202322:53Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRSSyros Pharmaceuticals Inc
19/12/202313:27Business WireSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:SYRSSyros Pharmaceuticals Inc
14/12/202322:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
12/12/202322:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
06/12/202313:00Business WireSyros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and AzacitidineNASDAQ:SYRSSyros Pharmaceuticals Inc
14/11/202313:30Business WireSyros Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
07/11/202313:30Business WireSyros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023NASDAQ:SYRSSyros Pharmaceuticals Inc
20/10/202322:15Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:SYRSSyros Pharmaceuticals Inc
02/10/202314:45Business WireSyros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical CompanyNASDAQ:SYRSSyros Pharmaceuticals Inc
08/08/202313:30Business WireSyros Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
01/08/202313:30Business WireSyros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023NASDAQ:SYRSSyros Pharmaceuticals Inc
08/06/202313:30Business WireSyros to Present at Sidoti June 2023 Virtual Small-Cap ConferenceNASDAQ:SYRSSyros Pharmaceuticals Inc
02/06/202322:28Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SYRSSyros Pharmaceuticals Inc
02/06/202322:14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SYRSSyros Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SYRS

La tua Cronologia

EU
XS1874835652
ABN Amro Bank NV 1.3% 03...
COIN
XCHUST
Chia Network
LSE
0JQ2
Kala Pharmaceuticals
LSE
0MQ9
Zci
COIN
FORCEEETH
Force Protocol
NYSE
KFS
Kingsway Financial Servi...
ASX
AUNNB
Aurumin
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network